291 related articles for article (PubMed ID: 7755657)
1. TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters.
Sugiyama Y; Ishikawa E; Odaka H; Miki N; Tawada H; Ikeda H
Atherosclerosis; 1995 Feb; 113(1):71-8. PubMed ID: 7755657
[TBL] [Abstract][Full Text] [Related]
2. TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters.
Sugiyama Y; Odaka H; Itokawa S; Ishikawa E; Tomari Y; Ikeda H
Atherosclerosis; 1995 Nov; 118(1):145-53. PubMed ID: 8579624
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs.
Kashiwa M; Masuyama Y; Miyauchi H; Uchida T; Naganuma S; Kakuta H; Terada M; Kiriyama T; Matsuda K; Ito N; Iizumi Y; Takenaka T
Jpn J Pharmacol; 1997 Jan; 73(1):41-50. PubMed ID: 9032133
[TBL] [Abstract][Full Text] [Related]
4. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.
Salisbury BG; Davis HR; Burrier RE; Burnett DA; Bowkow G; Caplen MA; Clemmons AL; Compton DS; Hoos LM; McGregor DG
Atherosclerosis; 1995 May; 115(1):45-63. PubMed ID: 7669087
[TBL] [Abstract][Full Text] [Related]
5. Effect of SMP-500, a novel acyl-coA:cholesterol acyltransferase inhibitor, on the cholesterol esterification and its hypocholesterolemic properties.
Ioriya K; Noguchi T; Muraoka M; Fujita K; Shimizu H; Ohashi N
Pharmacology; 2002 May; 65(1):18-25. PubMed ID: 11901297
[TBL] [Abstract][Full Text] [Related]
6. CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption.
Largis EE; Wang CH; DeVries VG; Schaffer SA
J Lipid Res; 1989 May; 30(5):681-90. PubMed ID: 2760542
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in cholesterol-fed rats, hamsters and rabbits.
Matsui Y; Horiuchi K; Yamamoto K; Kanai K
Jpn J Pharmacol; 2001 Apr; 85(4):423-33. PubMed ID: 11388647
[TBL] [Abstract][Full Text] [Related]
8. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.
Uchida T; Aoyama K; Watanabe T; Higuchi S
Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat.
Balasubramaniam S; Simons LA; Chang S; Roach PD; Nestel PJ
Atherosclerosis; 1990 May; 82(1-2):1-5. PubMed ID: 2360913
[TBL] [Abstract][Full Text] [Related]
10. A selective inhibitor of intestinal ACAT, EAB309 suppresses both intestinal and hepatic cholesterol output and stimulates chylomicron removal.
Umeda Y; Hirano T; Kako Y; Kamagata K; Okuyama K; Suzuki K
Life Sci; 1998; 63(13):PL187-95. PubMed ID: 9763214
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys.
Marzetta CA; Savoy YE; Freeman AM; Long CA; Pettini JL; Hagar RE; Inskeep PB; Davis K; Stucchi AF; Nicolosi RJ
J Lipid Res; 1994 Oct; 35(10):1829-38. PubMed ID: 7852860
[TBL] [Abstract][Full Text] [Related]
12. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol.
Riddell D; Bright CP; Burton BJ; Bush RC; Harris NV; Hele D; Moore UM; Naik K; Parrott DP; Smith C; Williams RJ
Biochem Pharmacol; 1996 Oct; 52(8):1177-86. PubMed ID: 8937424
[TBL] [Abstract][Full Text] [Related]
13. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
[TBL] [Abstract][Full Text] [Related]
14. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
Krause BR; Black A; Bousley R; Essenburg A; Cornicelli J; Holmes A; Homan R; Kieft K; Sekerke C; Shaw-Hes MK
J Pharmacol Exp Ther; 1993 Nov; 267(2):734-43. PubMed ID: 8246149
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of a direct effect on hepatic acyl CoA: cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster.
Burrier RE; Deren S; McGregor DG; Hoos LM; Smith AA; Davis HR
Biochem Pharmacol; 1994 Apr; 47(9):1545-51. PubMed ID: 8185666
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits.
Azuma Y; Kawasaki T; Ikemoto K; Obata K; Ohno K; Sajiki N; Yamada T; Yamasaki M; Nobuhara Y
Jpn J Pharmacol; 1998 Nov; 78(3):355-64. PubMed ID: 9869270
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N
J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of N-(3,5-dimethoxy-4-n-octyloxycinnamoyl)-N'-(3,4-dimethylphenyl)piperazine (YIC-C8-434), an acyl-CoA:cholesterol O-acyltransferase inhibitor, on cholesterol esterification in the intestine and liver.
Ohishi K; Sawada H; Yoshida Y; Yokoi W; Hatano H; Aiyama R; Watanabe T; Yokokura T
Biol Pharm Bull; 2003 Aug; 26(8):1125-8. PubMed ID: 12913263
[TBL] [Abstract][Full Text] [Related]
20. Novel acyl-CoA:cholesterol acyltransferase inhibitors. Synthesis and biological activity of 3-quinolylurea derivatives.
Tawada H; Harcourt M; Kawamura N; Kajino M; Ishikawa E; Sugiyama Y; Ikeda H; Meguro K
J Med Chem; 1994 Jun; 37(13):2079-84. PubMed ID: 8027989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
